{"id":"acalabrutinib-capsule","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Diarrhea"},{"rate":"15-25","effect":"Headache"},{"rate":"15-20","effect":"Fatigue"},{"rate":"10-15","effect":"Bruising/bleeding"},{"rate":"10-15","effect":"Infection"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL4747506","moleculeType":"Unknown","molecularWeight":"465.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Acalabrutinib covalently binds to BTK, a key enzyme in B-cell receptor signaling, preventing downstream activation of proliferation and survival pathways. This selective BTK inhibition leads to apoptosis of malignant B cells while sparing other immune cells, making it effective in BTK-dependent lymphoid cancers. The drug's selectivity for BTK over other kinases reduces off-target toxicity compared to earlier-generation BTK inhibitors.","oneSentence":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling in hematologic malignancies.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:26:25.783Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (CLL)"},{"name":"Small lymphocytic lymphoma (SLL)"},{"name":"Mantle cell lymphoma (MCL)"},{"name":"Marginal zone lymphoma (MZL)"}]},"trialDetails":[{"nctId":"NCT05057494","phase":"PHASE3","title":"A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-09-12","conditions":"Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","enrollment":607},{"nctId":"NCT04560322","phase":"PHASE2","title":"Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-10-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":40},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":"Waldenstrom Macroglobulinemia","enrollment":63},{"nctId":"NCT04008706","phase":"PHASE3","title":"Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-09-17","conditions":"Chronic Lymphocytic Leukemia","enrollment":552},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT04685915","phase":"PHASE2","title":"Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL","status":"WITHDRAWN","sponsor":"Inhye Ahn","startDate":"2021-02-18","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":""},{"nctId":"NCT03623373","phase":"PHASE2","title":"Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2018-11-29","conditions":"Mantle Cell Lymphoma","enrollment":13},{"nctId":"NCT04630756","phase":"PHASE1, PHASE2","title":"AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-17","conditions":"Advanced Haematological Malignancies","enrollment":40},{"nctId":"NCT04178798","phase":"PHASE3","title":"Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-12-09","conditions":"Chronic Lymphocytic Leukemia- Binet Staging System","enrollment":22},{"nctId":"NCT04646395","phase":"PHASE2","title":"Study of Acalabrutinib and Tafasitamab in MZL Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2021-10-20","conditions":"Marginal Zone Lymphoma","enrollment":26},{"nctId":"NCT04716075","phase":"PHASE2","title":"Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)","status":"COMPLETED","sponsor":"Polish Lymphoma Research Group","startDate":"2019-08-19","conditions":"Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease, Mantle Cell Lymphoma","enrollment":29},{"nctId":"NCT04930536","phase":"PHASE4","title":"Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-07-14","conditions":"Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma","enrollment":103},{"nctId":"NCT05950997","phase":"NA","title":"A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-04-16","conditions":"Chronic Lymphocytic Leukemia","enrollment":89},{"nctId":"NCT05038904","phase":"PHASE2","title":"Preventing Anaphylaxis With Acalabrutinib","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-12-16","conditions":"Food Allergy, Food Allergy Peanut","enrollment":10},{"nctId":"NCT04016805","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax","status":"TERMINATED","sponsor":"TG Therapeutics, Inc.","startDate":"2019-08-05","conditions":"Chronic Lymphocytic Leukemia","enrollment":41},{"nctId":"NCT04094142","phase":"PHASE2","title":"Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2019-07-09","conditions":"Non-hodgkin Lymphoma,B Cell","enrollment":66},{"nctId":"NCT03899337","phase":"PHASE2","title":"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2019-07-23","conditions":"Richter Syndrome","enrollment":105},{"nctId":"NCT04768985","phase":"PHASE1","title":"Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-25","conditions":"Bioequivalence","enrollment":66},{"nctId":"NCT05140096","phase":"PHASE1","title":"A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2020-01-03","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04914936","phase":"PHASE1","title":"A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-09-21","conditions":"Healthy Participants","enrollment":72},{"nctId":"NCT04905043","phase":"PHASE1","title":"A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-06-03","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT04901923","phase":"PHASE1","title":"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-03-15","conditions":"Healthy Participants","enrollment":59},{"nctId":"NCT04898101","phase":"PHASE1","title":"A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-03-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT04647669","phase":"PHASE3","title":"World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments","status":"UNKNOWN","sponsor":"The University of The West Indies","startDate":"2021-06-01","conditions":"Covid19","enrollment":100},{"nctId":"NCT04867941","phase":"PHASE1","title":"A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2014-10-21","conditions":"Hepatic Insufficiency","enrollment":18},{"nctId":"NCT04867980","phase":"PHASE1","title":"A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants","status":"COMPLETED","sponsor":"Acerta Pharma BV","startDate":"2016-04-01","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT04488016","phase":"PHASE1","title":"A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-06-24","conditions":"Bioavailability, B-cell Lymphoid Cancer","enrollment":54},{"nctId":"NCT04564040","phase":"PHASE1","title":"A Study in Healthy Subjects to Assess Bioavailability (Proportion of a Drug Which Enters the Circulation to Have an Active Effect) of Acalabrutinib Tablet and Protonpump Inhibitor Effect (Members of a Class of Medications That Inhibits in Gastric Acid Production) for Rabeprazole","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-10-12","conditions":"Mantle Cell Lymphoma, COVID-19","enrollment":20},{"nctId":"NCT04489797","phase":"PHASE1","title":"A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Infectious Disease","enrollment":35},{"nctId":"NCT04435483","phase":"PHASE1","title":"A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-22","conditions":"Pharmacokinetics, Bioavailability","enrollment":39},{"nctId":"NCT02570711","phase":"PHASE2","title":"Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Acerta Pharma BV","startDate":"2015-10-13","conditions":"Metastatic Pancreatic Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Calquence®","Calquence"],"phase":"marketed","status":"active","brandName":"Acalabrutinib capsule","genericName":"Acalabrutinib capsule","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK) that blocks B-cell proliferation and survival signaling in hematologic malignancies. Used for Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), Mantle cell lymphoma (MCL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}